sympozjum — diagnostyka i leczenie wtórnego i opornego nadciśnienia tętniczego

Programme


Download the programme in PDF
Friday, 20 October 2017
09.00–09.10Welcome and introduction
Andrzej Januszewicz
09.10–10.30
Session 1. Treatment of difficult-to-treat and resistant hypertension
Head: Alberto Morganti, Pierre-Francois Plouin, Andrzej Januszewicz
  1. Optimal pharmacological treatment — does it exist? (20 min)
    Aleksander Prejbisz, prof. nadzw.
  2. Why aldosterone antagonists are efficient in difficult-to-treat hypertension? (20 min)
    Andrzej Januszewicz
  3. Renal denervation 2017 — what have we learned from recent clinical trials? (20 min)
    Michel Azizi
  4. Aldosterone antagonists in patients with chronic kidney disease (20 min)
    Andrzej Więcek
10.30–10.40Coffee break
10.40–12.10
Session 2. Renovascular hypertension in 2017 — focus on fibromuscular dysplasia
Head: Małgorzata Szczerbo-Trojanowska, Andrzej Więcek
  1. Renovascular hypertension in 2017 — fibromuscular dysplasia or atherosclerosis? (20 min)
    Andrzej Januszewicz
  2. Fibromuscular dysplasia — is it a single disease? (20 min)
    Pierre-Francois Plouin
  3. ARCADIA-POL study — landscape of FMD in Poland (20 min)
    Andrzej Januszewicz
  4. Case presentations: Different clinical scenarios of FMD (20 min)
    Ewa Warchoł-Celińska, Łukasz Stryczyński, Łukasz Światłowski
  5. Discussion
12.10–12.30Coffee break
12.30–13.50
Session 3. Controversies in the management of primary aldosteronism
Head: Jacques Lenders, Michel Azizi, Aleksander Prejbisz, prof. nadzw.
  1. How to screen patients for primary aldosteronism? (20 min)
    Alberto Morganti
  2. Subtype evaluation and follow-up of patients with primary aldosteronism — did SPARTACUS and PASO studies change clinical approach? (20 min)
    Paolo Mulatero
  3. Genetics of primary aldosteronism — has the time come? (20 min)
    Tracy Williams
  4. Case presentations: Primary aldosteronism (15 min)
    Aleksander Prejbisz, prof. nadzw.
  5. Commentary (5 min)

    Expert panel

13.50–14.00Coffee break
14.00–15.40
Session 4. Management of endocrine hypertension
Head: Graeme Eisenhofer, Paolo Mulatero
  1. Screening for catecholamine producing tumors — tailoring biochemical methods for different clinical and genetic profiles (20 min)
    Graeme Eisenhofer
  2. Evaluation of incidentaloma — guidelines and reality (20 min)
    Lucyna Papierska
  3. Treatment and follow-up of patients with pheochromocytoma and paraganglioma (20 min)
    Jacques Lenders
  4. Case presentations: Pheochromocytoma and paraganglioma (20 min)
    Mariola Pęczkowska
  5. Commentary (5 min)

    Expert panel

  6. Case presentations: Cushing syndrome (10 min)
    Urszula Ambroziak
  7. Commentary (5 min)

    Expert panel

Friday, 20 October 2017
09.00–09.10
Welcome and introduction
Andrzej Januszewicz
09.10–10.30
Session 1. Treatment of difficult-to-treat and resistant hypertension
Head: Alberto Morganti, Pierre-Francois Plouin, Andrzej Januszewicz
  1. Optimal pharmacological treatment — does it exist? (20 min)
    Aleksander Prejbisz, prof. nadzw.
  2. Why aldosterone antagonists are efficient in difficult-to-treat hypertension? (20 min)
    Andrzej Januszewicz
  3. Renal denervation 2017 — what have we learned from recent clinical trials? (20 min)
    Michel Azizi
  4. Aldosterone antagonists in patients with chronic kidney disease (20 min)
    Andrzej Więcek
10.30–10.40
Coffee break
10.40–12.10
Session 2. Renovascular hypertension in 2017 — focus on fibromuscular dysplasia
Head: Małgorzata Szczerbo-Trojanowska, Andrzej Więcek
  1. Renovascular hypertension in 2017 — fibromuscular dysplasia or atherosclerosis? (20 min)
    Andrzej Januszewicz
  2. Fibromuscular dysplasia — is it a single disease? (20 min)
    Pierre-Francois Plouin
  3. ARCADIA-POL study — landscape of FMD in Poland (20 min)
    Andrzej Januszewicz
  4. Case presentations: Different clinical scenarios of FMD (20 min)
    Ewa Warchoł-Celińska, Łukasz Stryczyński, Łukasz Światłowski
  5. Discussion
12.10–12.30
Coffee break
12.30–13.50
Session 3. Controversies in the management of primary aldosteronism
Head: Jacques Lenders, Michel Azizi, Aleksander Prejbisz, prof. nadzw.
  1. How to screen patients for primary aldosteronism? (20 min)
    Alberto Morganti
  2. Subtype evaluation and follow-up of patients with primary aldosteronism — did SPARTACUS and PASO studies change clinical approach? (20 min)
    Paolo Mulatero
  3. Genetics of primary aldosteronism — has the time come? (20 min)
    Tracy Williams
  4. Case presentations: Primary aldosteronism (15 min)
    Aleksander Prejbisz, prof. nadzw.
  5. Commentary (5 min)

    Expert panel

13.50–14.00
Coffee break
14.00–15.40
Session 4. Management of endocrine hypertension
Head: Graeme Eisenhofer, Paolo Mulatero
  1. Screening for catecholamine producing tumors — tailoring biochemical methods for different clinical and genetic profiles (20 min)
    Graeme Eisenhofer
  2. Evaluation of incidentaloma — guidelines and reality (20 min)
    Lucyna Papierska
  3. Treatment and follow-up of patients with pheochromocytoma and paraganglioma (20 min)
    Jacques Lenders
  4. Case presentations: Pheochromocytoma and paraganglioma (20 min)
    Mariola Pęczkowska
  5. Commentary (5 min)

    Expert panel

  6. Case presentations: Cushing syndrome (10 min)
    Urszula Ambroziak
  7. Commentary (5 min)

    Expert panel




Strony konferencji Grupy Via Medica wykorzystują pliki cookies. Opcje dotyczące cookies można zmienić w ustawieniach przeglądarki internetowej.
Korzystanie z niniejszej strony bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie www.wszystkoociasteczkach.pl